Caribou Biosciences, Inc.
CRBU- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001619856
No open-market purchases or sales by Caribou Biosciences, Inc. insiders were filed in the last 90 days; 137 institutions reported holding it in 13F filings for Q2 2026, worth $84.8M in total; Maverick Capital is the only superinvestor holding it.
13F holders, Q1 2022
Institutional positions in Caribou Biosciences, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 104
- +12 vs. Q4 2021
- Shares held
- 34.1M
- +3.06M (+9.8%) vs. Q4 2021
- Total value
- $313.2M
- −$151.3M (−32.6%) vs. Q4 2021
- New holders
- 23
- 43 more added
- Sold out
- 11
- 18 more reduced
1 institution that held it in Q4 2021 haven't filed for Q1 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CRBU on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 137 | $84.8M |
| Q1 2026 | 137 | $71.3M |
| Q4 2025 | 124 | $58.8M |
| Q3 2025 | 117 | $87.0M |
| Q2 2025 | 129 | $51.2M |
| Q1 2025 | 131 | $45.8M |
| Q4 2024 | 133 | $93.1M |
| Q3 2024 | 129 | $103.1M |
| Q2 2024 | 140 | $87.6M |
| Q1 2024 | 151 | $343.0M |
| Q4 2023 | 144 | $395.8M |
| Q3 2023 | 126 | $338.5M |
| Q2 2023 | 121 | $185.5M |
| Q1 2023 | 126 | $238.3M |
| Q4 2022 | 133 | $273.8M |
| Q3 2022 | 113 | $456.8M |
| Q2 2022 | 120 | $203.0M |
| Q1 2022 | 104 | $313.2M |
| Q4 2021 | 93 | $464.7M |
| Q3 2021 | 88 | $704.7M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Caribou Biosciences, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Pictet Asset Management SA | 2,684,548 | $24.6M | 0.03% | +768,117+40.1% | Added |
| Avidity Partners Management LP | 2,819,067 | $25.9M | 0.57% | +145,000+5.4% | Added |
| BlackRock Inc. | 3,319,182 | $30.5M | 0.00% | +1,556,153+88.3% | Added |
| PFM Health Sciences, LP | 4,370,545 | $40.1M | 1.55% | +278,236+6.8% | Added |
| Coatue Management LLCSuperinvestorCoatue Management | 0 | $0 | 0.00% | −557,669−100.0% | Sold out |
| CloudAlpha Capital Management Limited/Hong Kong | 0 | $0 | 0.00% | −415,000−100.0% | Sold out |
| Victory Capital Management Inc | 0 | $0 | 0.00% | −81,160−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −76,691−100.0% | Sold out |
| Pura Vida Investments, LLC | 0 | $0 | 0.00% | −41,932−100.0% | Sold out |
| Ergoteles LLC | 0 | $0 | 0.00% | −41,487−100.0% | Sold out |
| DekaBank Deutsche Girozentrale | 0 | $0 | 0.00% | −22,000−100.0% | Sold out |
| Atom Investors LP | 0 | $0 | 0.00% | −16,323−100.0% | Sold out |
| Royce & Associates LP | 0 | $0 | 0.00% | −12,900−100.0% | Sold out |
| KCL Capital, L.P. | 0 | $0 | 0.00% | −12,000−100.0% | Sold out |
| Eaton Vance Management | 0 | $0 | 0.00% | −425−100.0% | Sold out |
| AlphaCentric Advisors LLC | – | – | – | – | Not filed |